UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.CTSU-E2211Principal InvestigatorBergsland, Emily
PhaseII (Cancer Control)
Age GroupAdultScopeNational
Secondary Protocol No.E2211
TitleA Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
ObjectiveTo evaluate PFS associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors.
Key EligibilityAge: 18+ * Histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma * Must not have received prior temozolomide, dacarbazine (DTIC), or capecitabine, or 5-FU (fluorouracil) therapy
Applicable Disease SitesPancreas
Participating InstitutionsMt. Zion
Eligibility DocumentCTSU-E2211_CTGovEligibility_NCT01824875.doc